Edition:
India

Albireo Pharma Inc (ALBO.OQ)

ALBO.OQ on NASDAQ Stock Exchange Capital Market

23.15USD
24 Jan 2020
Change (% chg)

$0.00 (+0.00%)
Prev Close
$23.15
Open
$23.77
Day's High
$23.83
Day's Low
$23.01
Volume
9,654
Avg. Vol
19,969
52-wk High
$38.48
52-wk Low
$16.26

Latest Key Developments (Source: Significant Developments)

Albireo Provides Mid-Year Clinical Development Update
Wednesday, 10 Jul 2019 

July 9 (Reuters) - Albireo Pharma Inc ::ALBIREO PROVIDES MID-YEAR CLINICAL DEVELOPMENT UPDATE.ALBIREO PHARMA INC - EXPECTS ODEVIXIBAT PEDFIC 1 PHASE 3 TOPLINE DATA MID-2020 -.ALBIREO PHARMA INC - SITE ACTIVATED FOR ODEVIXIBAT PEDFIC 2 EXPANDED OPEN-LABEL COHORT.ALBIREO PHARMA INC - ODEVIXIBAT BILIARY ATRESIA PIVOTAL TRIAL EXPECTED TO BEGIN IN 2020.ALBIREO PHARMA INC - MOVES INTO NASH WITH INITIATION OF ELOBIXIBAT PHASE 2 TRIAL.ALBIREO PHARMA INC - ENCOURAGED WITH RECRUITING EFFORTS BY PARTICIPATING SITES IN OUR PHASE 3 TRIAL FOR ODEVIXIBAT IN PFIC.  Full Article

Albireo Expects Current Cash Balance To Be Sufficient To Meet Operating Needs Into 2021
Thursday, 7 Mar 2019 

March 7 (Reuters) - Albireo Pharma Inc ::ALBIREO REPORTS YEAR-END 2018 FINANCIAL RESULTS AND PROVIDES PIPELINE UPDATE.ALBIREO PHARMA INC - A4250 PHASE 3 PFIC PIVOTAL PROGRAM ON TARGET FOR END OF '19/EARLY '20 TOPLINE READOUT.ALBIREO PHARMA INC - HAD CASH AND CASH EQUIVALENTS AT DECEMBER 31, 2018 OF $163.9 MILLION, COMPARED TO $53.2 MILLION AT DECEMBER 31, 2017..ALBIREO PHARMA INC - FOR FULL YEAR 2019, ANTICIPATE TOTAL EXPENSES, INCLUDING RESEARCH AND DEVELOPMENT AND G&A EXPENSES, TO BE IN RANGE OF $75-$80 MILLION.ALBIREO PHARMA INC - EXPECT CURRENT CASH BALANCE TO BE SUFFICIENT TO MEET OUR OPERATING NEEDS INTO 2021..  Full Article

Albireo Pharma Inc Files For Mixed Shelf Of Up To $200 Million – SEC Filing
Thursday, 7 Mar 2019 

March 6 (Reuters) - Albireo Pharma Inc ::ALBIREO PHARMA INC FILES FOR MIXED SHELF OF UP TO $200 MILLION – SEC FILING.  Full Article

Albireo Pharma Granted Orphan Designation By European Commission
Tuesday, 18 Dec 2018 

Dec 18 (Reuters) - Albireo Pharma Inc ::ALBIREO GRANTED ORPHAN DESIGNATION BY EUROPEAN COMMISSION FOR LEAD PRODUCT CANDIDATE A4250 FOR TREATMENT OF BILIARY ATRESIA.ALBIREO PHARMA - PLAN TO EXPAND DEVELOPMENT OF A4250 IN RARE CHOLESTATIC LIVER DISEASES IN 2019.ALBIREO PHARMA - ORPHAN DESIGNATION PROVIDES 10 YEARS MARKET EXCLUSIVITY UPON APPROVAL PLUS 2 YEARS UPON COMPLETION OF PEDIATRIC INVESTIGATION PLAN.  Full Article

Albireo Q3 Loss Per Share $1.17
Tuesday, 13 Nov 2018 

Nov 13 (Reuters) - Albireo Pharma Inc ::ALBIREO REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $1.17.Q3 REVENUE $237,000.Q3 REVENUE VIEW $892,000 -- THOMSON REUTERS I/B/E/S.Q3 EARNINGS PER SHARE VIEW $-0.98 -- THOMSON REUTERS I/B/E/S.ODEVIXIBAT SELECTED AS INTERNATIONAL NONPROPRIETARY NAME (INN) FOR A4250.A4250 GRANTED FAST TRACK AND ADDITIONAL ORPHAN DRUG DESIGNATIONS.A4250 PHASE 3 TRIAL PROGRESSING AS PLANNED, NEW NATURAL HISTORY DATA PRESENTED AT AASLD.ALBIREO PHARMA - HAD CASH AND CASH EQUIVALENTS AT SEPT 30, 2018 OF $173.6 MILLION, COMPARED TO $53.2 MILLION AT DEC 31, 2017.ALBIREO PHARMA - EXPECT CURRENT CASH BALANCE TO BE SUFFICIENT TO MEET OPERATING NEEDS INTO 2021.ALBIREO PHARMA - FOR FY 2018, ANTICIPATE TOTAL EXPENSES, INCLUDING RESEARCH AND DEVELOPMENT AND G&A EXPENSES, TO BE AT HIGH END OF RANGE OF $45 MILLION -$50 MILLION.  Full Article